Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Blueprint Medi Cm ST (BPMC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,616,208
  • Shares Outstanding, K 39,200
  • Annual Sales, $ 27,770 K
  • Annual Income, $ -72,500 K
  • 36-Month Beta 1.26
  • Price/Sales 90.75
  • Price/Cash Flow 0.00
  • Price/Book 7.37

Price Performance

See More
Period Period Low Period High Performance
1-Month
61.58 +7.45%
on 11/15/17
74.42 -11.09%
on 11/06/17
+1.24 (+1.91%)
since 10/17/17
3-Month
41.41 +59.79%
on 08/21/17
74.42 -11.09%
on 11/06/17
+23.42 (+54.78%)
since 08/17/17
52-Week
25.08 +163.84%
on 12/07/16
74.42 -11.09%
on 11/06/17
+30.17 (+83.81%)
since 11/17/16

Most Recent Stories

More News
Featured Company News - Blueprint Medicines Announced New Data from Ongoing Phase-1 Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors

Research Desk Line-up: Puma Biotechnology Post Earnings Coverage

PBYI : 105.50 (+2.28%)
BPMC : 66.17 (-0.85%)
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across Spectrum of KIT and PDGFRa Genotypes

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1 clinical data...

BPMC : 66.17 (-0.85%)
Blueprint Medicines Announces Publication of BLU-285 Translational Data

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the publication of translational...

BPMC : 66.17 (-0.85%)
Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting and Exposition

Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that updated data from its...

BPMC : 66.17 (-0.85%)
Blueprint Medicines Reports Third Quarter 2017 Financial Results

Blueprint Medicines Corporation (NASDAQ:BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided...

BPMC : 66.17 (-0.85%)
Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will host a live...

BPMC : 66.17 (-0.85%)
Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced the appointment of Christopher...

BPMC : 66.17 (-0.85%)
Stocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and Cytokinetics

If you want a Stock Review on AVIR, BPMC, CALA, or CYTK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, September 20, 2017, the...

AVIR : 0.56 (-1.58%)
CYTK : 11.80 (+5.83%)
BPMC : 66.17 (-0.85%)
CALA : 10.27 (+4.80%)
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced updated data from its ongoing...

BPMC : 66.17 (-0.85%)
Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that Jeff Albers,Blueprint...

MS : 48.70 (+0.21%)
BPMC : 66.17 (-0.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA.

See More

Key Turning Points

2nd Resistance Point 69.38
1st Resistance Point 67.77
Last Price 66.17
1st Support Level 64.94
2nd Support Level 63.72

See More

52-Week High 74.42
Last Price 66.17
Fibonacci 61.8% 55.57
Fibonacci 50% 49.75
Fibonacci 38.2% 43.93
52-Week Low 25.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart